Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Material Safety Data Sheet(MSDS) Questions And Answer Well-known Reagent Company Product Information
WebSite >  CAS DataBase List  > 60142-96-3

60142-96-3

Supplier Related Products Identification Chemical Properties Safety Data Raw materials And Preparation Products Material Safety Data Sheet(MSDS) Questions And Answer Well-known Reagent Company Product Information

Product Image

Identification

Name
Gabapentin hydrochloride
CAS
60142-96-3
Synonyms
1-(AMINOMETHYL)CYCLOHEXANEACETIC ACID
(1-AMINOMETHYL-CYCLOHEXYL)-ACETIC ACID
AKOS 92109
GABAPENTIN
GABAPENTINE
GABAPENTIN HYDROCHLORIDE
GOE-3450
NEURONTIN
1-(aminomethyl)-cyclohexaneaceticaci
ci945
gabapentino
go3450
goe2450
Gababentin
GABAPENTIN (1-(AMINOMETHYL)-CYCLOHEXANEA CETIC ACID) \ NEURONTIN
GABAPENTIN, USP STANDARD
GABAPENTIN, RELATED COMPOUND A 3,3-PENTAMETHYLENE-5-BUTYROLACTAM USP STANDARD
Gabapentin&IntCdaCam
1-(Aminomethyl)cyclohexaneacetic Acid, Neurontin, GOE-3450
Cyclohexaneacetic acid, 1-(aminomethyl)-
EINECS(EC#)
262-076-3
Molecular Formula
C9H18ClNO2
MDL Number
MFCD00865286
Molecular Weight
207.7
MOL File
60142-96-3.mol

Chemical Properties

Appearance
White Crystalline Solid
mp 
162°C
solubility 
H2O: 10 mg/mL

form 
solid

color 
off-white

Usage
Amino acid structurally related to-Aminobutyric Acid (GABA), designed to cross the blood brain barrier. Used as an anticonvulsant
Merck 
4319
CAS DataBase Reference
60142-96-3(CAS DataBase Reference)

Safety Data

Hazard Codes 
T,Xi
Risk Statements 
R61:May cause harm to the unborn child.
R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Statements 
S53:Avoid exposure-obtain special instruction before use .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36:Wear suitable protective clothing .
WGK Germany 
3

RTECS 
GU6496000

HS Code 
29224900
Hazardous Substances Data
60142-96-3(Hazardous Substances Data)

Raw materials And Preparation Products

Material Safety Data Sheet(MSDS)

Questions And Answer

Description
Gabapentin is a second- generation antiepileptic drug (AED) known under the proprietary brand name of Neurontin® (Pfizer, New York, NY) in the UK and USA.
Generic formulation
MHRA/ CHM advice to minimize risk when switching patients with epilepsy between different manufacturers’ products (including generic products):
  • It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns, such as patient anxiety and risk of confusion/ dosing error.

Indications
Epilepsy: monotherapy or adjunctive therapy of focal seizures with or without secondary generalization. Recommendations summarized from NICE (2012)
  • Seizure types: adjunctive (focal seizures), contraindicated (generalized tonic- clonic seizures generalized tonic- clonic seizures if there are absence or myoclonic seizures, or if juvenile myoclonic epilepsy is suspected, tonic/ atonic seizures, absence seizures, myoclonic seizures).
  • Epilepsy types: adjunctive (benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, late- onset childhood occipital epilepsy), contraindicated (absence syndromes, juvenile myoclonic epilepsy, idiopathic generalized epilepsy, Dravet syndrome, Lennox– Gastaut syndrome)
  •  Psychiatry— treatment of anxiety disorders (unlicensed); treatment of alcohol withdrawal symptoms (unlicensed).
  •  Neurology— treatment of neuropathic pain and restless leg syndrome (unlicensed) and prophylaxis of migraine (unlicensed).

Dose titration
Monotherapy or adjunctive therapy
300 mg od for day 1300 mg bd for day 2300 mg td for day 3 (or 300 mg td for day 1), then increased by 300 mg every 2– 3 days, divided into three doses; usual maintenance 900– 3600 mg daily, divided into three doses (max. 4800 mg daily) If gabapentin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week, independent of the indication.
Cautions
  • Patients with a history of psychotic illness.
  • Patients with mixed seizures (including absences).
  • Patients with diabetes mellitus.
  • Elderly patients.

Interactions
With AEDs
Nil.

With other drugs
  • Patients who require concomitant treatment with opioids should be carefully observed for signs of respiratory depression and/ or sedation, and the dose of gabapentin or opioid should be reduced appropriately
  • Co-administration of gabapentin with antacids containing aluminium and magnesium, reduces gabapentin bioavailability up to 24%, and it is therefore recommended that gabapentin be taken at the earliest 2 hours following antacid administration

With alcohol/food
There are no known specific interactions between alcohol and gabapentin and there are no specific foods that must be excluded from diet when taking gabapentin.
Special populations
Renal impairment
Reduce maintenance dose according to degree of reduction in creatinine clearance.

Pregnancy
  • The dose of gabapentin should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
  • No definite conclusion can be made as to whether gabapentin is associated with an increased risk of congenital malformations when taken during pregnancy. Gabapentin should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.
  • Gabapentin is excreted in human milk. Because the effect on the breastfed infant is unknown, gabapentin should be used in breastfeeding mothers with caution and only if the benefits clearly outweigh the risks.

Behavioural and cognitive effects in patients with epilepsy
Gabapentin has a relatively favourable behavioural profile, although paradoxical hyperactivity, irritability and aggression have been occasionally reported, especially in patients with severe intellectual disabilities. The cognitive profile of gabapentin is equally favourable, as this AED has been associated with only minor cognitive difficulties (mainly in the attention domain).
Psychiatric use
Although gabapentin has no approved indications in psychiatry, it has shown efficacy in the treatment of anxiety disorders, especially social phobia. Other offlabel uses include other anxiety disorders (panic disorder, post- traumatic stress disorder), alcohol dependence and withdrawal, behavioural and psychological symptoms of dementia, and aggression. Gabapentin has also been proposed to be useful in the maintenance treatment of bipolar disorder as adjunctive therapy.

Well-known Reagent Company Product Information

SupplierMore